Free shipping on orders over $200
Free shipping on orders over $200
Molecular Weight
Purity
Storage
Appearance
Solubility
01
The Tesamorelin + Ipamorelin blend is a two-component reference material that combines agonists for two different receptors in the growth hormone axis. Tesamorelin is a full-length GHRH(1–44) analogue that acts on the GHRH receptor; Ipamorelin is a small, selective peptide that acts on the ghrelin receptor (GHS-R1a).
Supplying both in one lyophilized material gives a standardised starting point for studying combined activation of the two pathways, and for testing whether the two peptides remain stable and recoverable when formulated together. Each component is described in full on its own reference page. This blend is supplied as a lyophilized reference material for in vitro research only.
02
The two components are very different molecules, which shapes how the blend is handled and analysed.
Tesamorelin
A 44-residue peptide (5135.9 g/mol) carrying the full GHRH sequence with a trans-3-hexenoyl group on the N-terminus. It contains one methionine (Met27), which is the main oxidation risk in the blend.
Ipamorelin
A five-residue peptide (711.85 g/mol), Aib-His-D-2-Nal-D-Phe-Lys-NH₂, with two D-amino acids and an N-terminal Aib that make it resistant to proteases. Its naphthalene ring absorbs strongly in the UV.
Size difference
Tesamorelin is roughly seven times heavier than Ipamorelin. This large gap in size and hydrophobicity makes the two components easy to separate and quantify individually.
03
Research interest in the blend comes from the two components acting through different receptors and signalling routes.
Two receptor pathways
Tesamorelin activates the Gs-coupled GHRH receptor, raising cAMP. Ipamorelin activates the Gq-coupled ghrelin receptor, triggering phospholipase C, IP₃ and calcium release.
Combined activation
Studies in pituitary cell preparations have examined whether activating both receptors together gives additive or greater-than-additive growth hormone release compared with each peptide alone. A pre-blended material makes such single-versus-combined comparisons easier to standardise.
Co-formulation behaviour
Stability studies check whether the two peptides affect each other in the dried or reconstituted state, for example in recovery, degradation rate or solubility.
All research context described here refers to controlled in vitro experimental systems.
04
Two-component HPLC methods
A practical test sample for developing and validating methods that quantify a large and a small peptide in one run.
System suitability
Covers a wide molecular-weight range (about 0.7 to 5.1 kDa) in a single injection, useful for checking HPLC and LC-MS performance.
Co-formulation stability
Used in stress studies to see whether blending changes the degradation of either component, particularly Met27 oxidation in Tesamorelin.
Dual-pathway pharmacology
A standardised mixed-agonist preparation for comparing combined and single-agent receptor activation in pituitary cell models.
05
Storage
Store the sealed vial at −20 °C, desiccated and protected from light. Let it reach room temperature before opening to avoid condensation.
Reconstitution
Both components are water-soluble. Dissolve in water or a near-neutral aqueous buffer with gentle swirling; avoid vigorous shaking, which can promote aggregation of Tesamorelin.
Oxidation
Tesamorelin’s Met27 is the most sensitive site in the blend. Minimise light and air exposure and avoid peroxide-containing reagents.
Solutions
Divide into single-use aliquots after reconstitution and freeze; avoid repeated freeze–thaw cycles. Use low-binding polypropylene labware.
06
Each component is identified and measured separately within the mixture.
HPLC
Reversed-phase C18 with an acetonitrile/water gradient resolves the two peaks easily. Detection at 214 nm covers both; 280 nm adds selectivity for their aromatic residues.
Component ratio
Peak areas, calibrated against individual reference standards for each peptide, are used to confirm the ratio of the two components.
Mass spectrometry
Ipamorelin appears as [M+H]⁺ at m/z 712.4. Tesamorelin appears as a series of multiply charged ions, roughly m/z 640–1290 for charge states +4 to +8, so the two do not overlap.
Purity
Purity and impurity profiles are assessed for each component against its own specification, including Met27 oxidation of Tesamorelin and epimers of Ipamorelin.
07
Two peptides: Tesamorelin, a GHRH-receptor agonist, and Ipamorelin, a ghrelin-receptor agonist. The amount of each component is stated on the product label and certificate of analysis.
They act on different receptors and signalling pathways (GHRH receptor/cAMP and ghrelin receptor/calcium). A pre-blended material provides a standard sample for studying combined activation of both pathways.
By reversed-phase HPLC, where their large difference in size and hydrophobicity gives two well-separated peaks, each quantified against its own reference standard. Mass spectrometry confirms both identities.
Usually Tesamorelin, because of its oxidation-prone Met27 and its larger size. Ipamorelin, with its D-amino acids and Aib residue, is comparatively robust.
No. It is supplied strictly as a reference material for laboratory and analytical research and is not for human or animal use.
Tesamorelin + Ipamorelin Blend Research Reference. (2026). Pure Peptides Labs Research Catalogue. Retrieved from https://purepeptideslabs.net/research-catalogue/growth-hormone-axis-research-peptides/tesamorelin-ipamorelin-blend/
Materials listed on this platform are supported by independent testing and published documentation for laboratory research contexts.
